Floatz logo

LENVATINIB

Sarcoma

Mayo ClinicSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

92 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2BB
Inno-206
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →